News
The European project “Oncommun-ICOnnecta’t” receives two International awards
The last month this project, developed by the Catalan Institute of Oncology and IDIBELL, with the collaboration in Portugal of the Pedro Nuñez Institute, has received the awards ” Invertir me Saúde 2020″ and “HINTT Award”.
IDIBELL and its fight against Covid-19
The Covid-19 pandemic has created a big social emergency, and research progress is the only solution to face it and control it definitively. From the beginning of the crisis, IDIBELL has adapted to the new needs creating new lines of research to fight the virus and applying all the knowledge to the pandemic.
Identified a biomarker that predicts the increase in malignancy that antiangiogenic therapy can cause in kidney cancers
An IDIBELL-ICO study has identified that not only that antiangiogenic chemotherapy can induce more aggressiveness and malignancy in kidney tumors, but also, they have identified a biomarker to predict in which patients this may happen. These discoveries are another step towards making cancer therapy more personalized every day.
Jordi Carratalà and Fernando Fernández Aranda, new professors at the University of Barcelona
Drs. Jordi Carratalà, the coordinator of the Infectious Diseases and Transplants Program, and Fernando Fernández Aranda, principal investigator of the Psychiatry and Mental Health Group, both from IDIBELL and the Bellvitge University Hospital, have recently won the respective chairs of the Faculty of Medicine and Sciences of the Health of the University of Barcelona (UB).
Researchers discover a mechanism that can increase survival in patients with advanced prostate cancer
The validation of this cellular mechanism will permit the identification of patients who have developed resistance to standard treatments and the implementation of more personalized medicine for prostate cancer.
Funding to study new drugs against autoimmune diseases
IDIBELL researcher Josep Maria Aran and his research group will receive 100,000 euros from the aid Product from the AGAUR agency of the Generalitat de Catalunya. They will study two molecules that act on the immune system as possible treatments for autoimmune diseases.
The lack of interaction between two neuronal receptors is a determining factor in schizophrenia
The interaction of these two receptors leads to the inhibition of the dopaminergic pathway, which in this disorder is abnormally active. This discovery opens the door to the design of new drugs for the treatment of schizophrenia that acts on this interaction.
IDIBELL receives european funding to promote open science and innovation
The project aims to create online courses that help pre-doctoral researchers to acquire transversal skills for the future of their careers.
Blood concentrations of polyphenols are not clearly related to the risk of thyroid cancer
Although polyphenols have shown anticarcinogenic activity in previous in vitro studies, the epidemiological study led by IDIBELL and the ICO has found no association between their concentration in blood and thyroid cancer.